Glaxo pipeline gets a boost from US

Pharmaceuticals giant GlaxoSmithKline said yesterday that US regulators have given breakthrough therapy status for its investigational compound drisapersen for the potential treatment of patients with duchenne muscular dystrophy (DMD). The US Food and Drug Administration created the “breakthrough therapy” designation earlier this year for medicines deemed likely to demonstrate “substantial improvement” over existing drugs. DMD is a debilitating childhood neuromuscular disease.